The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -9.61 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.67 — no flag raisedOK
- Earnings quality 77/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Ultragenyx Pharmaceutical Inc. reports it. History and quarterly detail are in the app.
- Collaboration And Royalty$481.0M
- Product$369.0M
- Royalty$304.0M
- Non Cash Royalty$112.0M
Leadership changes
From Ultragenyx Pharmaceutical Inc.'s own filings, the day they're filed.
- Howard Horn · Chief Financial Officer · appointmenteff. 2023-10-16
- Howard Horn · Chief Financial Officer · appointmenteff. 2023-10-16
- Covered Transaction · departure
Latest filings
- 8-K · Company announcement2026-09-02
- 8-K · Company announcement2026-08-19
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-04
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Ultragenyx Pharmaceutical Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Ultragenyx Pharmaceutical Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.